Breakthrough in Mesothelioma Treatment: Cellectis’ Promising CAR-T Therapy
|

Breakthrough in Mesothelioma Treatment: Cellectis’ Promising CAR-T Therapy

ByHolly Zink

Mesothelioma is a challenging cancer with limited treatment options. Yet, recent advancements in CAR-T therapy are bringing new hope to the table. There is a breakthrough that holds the potential for improving mesothelioma treatment outcomes. Data comes from Journal for ImmunoTherapy of Cancer. CAR-T Therapy: A New Frontier for Mesothelioma CART T-cell therapy for mesothelioma is a type of immunotherapy. It starts with T-cells from the patient’s blood. Scientists alter the cells to recognize certain antigens on the surface of cancer cells. Then they give them back to the patient. In the case of mesothelioma, the main targeted antigen is mesothelin. Mesothelioma patients tend to produce extra mesothelin. This protein helps drive the growth and spread of their cancer. People with high levels…

New CAR-T Cell Therapy for Mesothelioma Circumvents Immune Suppression
| | | | |

New CAR-T Cell Therapy for Mesothelioma Circumvents Immune Suppression

ByAlex Strauss

A new cancer treatment based on CAR-T cell therapy may have found a way to undermine a key protective mechanism in mesothelioma tumors. The treatment is called UCARTMESO. It is being developed by a French biopharmaceutical company called Cellectis. UCARTMESO targets cells that overexpress the protein mesothelin. It undermines some key genes in these cells preventing them from sending immune suppressive signals.  Immune suppressive elements in the area surrounding mesothelioma tumors have historically kept CAR-T cell therapy from working as well as it does for some other types of cancer.  But the developers of UCARTMESO say their approach may finally make CAR-T cell therapy a viable option for patients fighting asbestos cancer.  They presented their findings at the Society for…